ConductScience.org, home

Paper36979666

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis.

Picchianti Diamanti A and 21 others. Biomedicines, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis. Papers, record 36979666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979666

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Third Dose of BNT162b2 COVID-19 Vaccine Does Not "Boost" Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis.
PubMed
Journal
Biomedicines
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2023-03-31
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Picchianti Diamanti AAndreahttps://orcid.org/0000-0002-8552-4641
2Navarra AAssuntahttps://orcid.org/0000-0002-3662-4312
3Cuzzi GGilda
4Aiello AAlessandrahttps://orcid.org/0000-0003-2681-9383
5Salemi SSimonetta
6Di Rosa RRoberta
7De Lorenzo CChiara
8Vio DDaniele
9Sebastiani GGiandomenicohttps://orcid.org/0000-0003-2969-6649
10Ferraioli MMario
11Benucci MMaurizio
12Li Gobbi FFrancesca
13Cantini FFabrizio
14Polidori VVittoria
15Simmaco MMaurizio
16Cialdi EEsmeralda
17Scolieri PPalmahttps://orcid.org/0000-0002-2055-7282
18Bruzzese VVincenzo
19Nicastri EEmanuelehttps://orcid.org/0000-0002-5606-8712
20D'Amelio RRaffaelehttps://orcid.org/0000-0003-0669-2629

Source PubMed

See all 22 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
871029Italian Ministry of Health, by the European Union's Horizon 2020 research and innovation pro-gramme under EVA GLOBAL grantPubMed

Source PubMed

Download CSV of grants

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135168944Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.Ann Rheum Dis2022https://conductscience.org/library/papers/35168944PubMed
234179831Adverse events after first COVID-19 vaccination in patients with autoimmune diseases.Lancet Rheumatol2021https://conductscience.org/library/papers/34179831PubMed
334127481Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.Ann Rheum Dis2021https://conductscience.org/library/papers/34127481PubMed
435746461
Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study.
Vaccines (Basel)2022https://conductscience.org/library/papers/35746461PubMed
534757289A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.J Autoimmun2021https://conductscience.org/library/papers/34757289PubMed
636315075COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.Rheumatology (Oxford)2023https://conductscience.org/library/papers/36315075PubMed
734358147
Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study.
Vaccines (Basel)2021https://conductscience.org/library/papers/34358147PubMed
8208725952010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Arthritis Rheum2010https://conductscience.org/library/papers/20872595PubMed
934474172Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis.Autoimmun Rev2022https://conductscience.org/library/papers/34474172PubMed
1036473651Efficacy and safety of COVID-19 vaccines.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/36473651PubMed
11314130052019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.Ann Rheum Dis2020https://conductscience.org/library/papers/31413005PubMed
1234476603Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.Rheumatol Int2021https://conductscience.org/library/papers/34476603PubMed
1336367013Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.Euro Surveill2022https://conductscience.org/library/papers/36367013PubMed
1434572349
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies.
Biomedicines2021https://conductscience.org/library/papers/34572349PubMed
1535309297Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.Front Immunol2022https://conductscience.org/library/papers/35309297PubMed
1633494477Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity.Vaccines (Basel)2021https://conductscience.org/library/papers/33494477PubMed
1735471956Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.JCI Insight2022https://conductscience.org/library/papers/35471956PubMed
1820521925Could autoimmunity be induced by vaccination?Int Rev Immunol2010https://conductscience.org/library/papers/20521925PubMed
1934594343ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients.Front Immunol2021https://conductscience.org/library/papers/34594343PubMed
2034142203Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.Rheumatol Int2021https://conductscience.org/library/papers/34142203PubMed

See all 57 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41289027Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.JCI Insight2025https://conductscience.org/library/papers/41289027PubMed
38932401Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.Vaccines (Basel)2024https://conductscience.org/library/papers/38932401PubMed
38907947What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.Drug Saf2024https://conductscience.org/library/papers/38907947PubMed
38137412Editorial to the Special Issue "Clinical Immunology in Italy, with Special Emphasis to Primary and Acquired Immunodeficiencies: A Commemorative Issue in Honor of Prof. Fernando Aiuti".Biomedicines2023https://conductscience.org/library/papers/38137412PubMed
38006015
Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine.
Vaccines (Basel)2023https://conductscience.org/library/papers/38006015PubMed
37583697Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.Front Immunol2023https://conductscience.org/library/papers/37583697PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36979666

GET https://conductscience.org/api/papers/v1/36979666/authors?page=2